Antimicrobial resistance is one of the most important global public health challenges. Several different alternatives to conventional antibiotics are under development; Bacteriophage therapy is one of them. Currently, therapeutic use of phages is restrained by regulatory hurdles and, largely limited to sporadic authorization in compassionate use or under temporary approval as new drugs in Europe and the US. Although bacteriophage therapy seems to be safe and clinical results of phage treatment are promising, future data from high-quality (randomized controlled) trials could provide a better understanding of the reasonable minimal criteria required for expansion of bacteriophage therapy.